Abstract
Background/Aims: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been shown to inhibit growth and to induce apoptosis in human hepatocellular carcinoma (HCC) cells. However, the potential benefit of pravastatin in HCC patients has still not been characterized, which prompted us to test the efficacy of pravastatin in patients with advanced HCC. Methods: We investigated prospectively a cohort of 183 HCC patients who had been selected for palliative treatment by transarterial chemoembolization (TACE). Fifty-two patients received TACE combined with pravastatin (20–40 mg/day) and 131 patients received chemoembolization alone. Six independent predictors of survival according to the Vienna survival model for HCC were equally distributed in both groups. Results: During the observation period of up to 5 years, 31 (23.7%) out of 131 patients treated by TACE alone and 19 (36.5%) out of 52 patients treated by TACE and pravastatin survived. Median survival was significantly longer in HCC patients treated by TACE and pravastatin (20.9 months, 95% CI 15.5–26.3, p = 0.003) than in HCC patients treated by TACE alone (12.0 months, 95% CI 10.3–13.7). Conclusion: Combined treatment of chemoembolization and pravastatin improves survival of patients with advanced HCC in comparison to patients receiving chemoembolization alone.
Journal Section:
Original Paper
References
1.
Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–285.
[PubMed]
2.
Befeler AS, di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609–1619.
[PubMed]
3.
Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907–1917.
[PubMed]
4.
Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ III: Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005;129:486–493.
[PubMed]
5.
Groupe d’Etude et de Traitement du HCC: A comparison of lipiodol chemoembolization and conservative treatment for unresectable HCC. N Engl J Med 1995;332:1256–1261.
[PubMed]
6.
Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129–134.
[PubMed]
7.
Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578–1583.
[PubMed]
8.
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J; Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.
[PubMed]
9.
Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–442.
[PubMed]
10.
Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y; Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 2006;131:461–469.
[PubMed]
11.
Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001;7:2067–2075.
[PubMed]
12.
Gebhardt A, Niendorf A: Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines. J Cancer Res Clin Oncol 1995;121:343–349.
[PubMed]
13.
Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y: Modulation of the mevalonate pathway and cell growth by pravastatin and D-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994;69:1015–1020.
[PubMed]
14.
Paragh G, Kertai P, Kovacs P, Paragh G Jr, Fulop P, Foris G: HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res 2003;23:3949–3954.
[PubMed]
15.
Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Vidaud M, Rosenbaum J: Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007;46:69–76.
[PubMed]
16.
Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 2001;84:886–891.
[PubMed]
17.
Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A: Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48:103–109.
[PubMed]
18.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421–430.
[PubMed]
19.
Johnson PJ: Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002;51:459–462.
[PubMed]
20.
Rabe C, Lenz M, Schmitz V, Pilz T, Fimmers R, Sauerbruch T, Caselmann WH: An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2003;15:1305–1315.
[PubMed]
21.
Ryder SD, Rizzi PM, Metivier E, Karami J, Williams R: Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut 1996;38:125–128.
[PubMed]
22.
Sutter AP, Maaser K, Höpfner M, Huether A, Schuppan D, Scherübl H: Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors: synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005;43:808–816.
[PubMed]
23.
Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, Franklin RA, Robinson PJ, McMahon M, McCubrey JA: Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001;7:2898–2907.
[PubMed]
24.
Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA: Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004;104:1816–1824.
[PubMed]
25.
Jakobisiak M, Golab J: Potential antitumor effects of statins. Int J Oncol 2003;23:1055–1069.
[PubMed]
26.
Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE: Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003;101:3628–3634.
[PubMed]
27.
Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakóbisiak M, Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 2004;24:1149–1157.
[PubMed]
28.
Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakóbisiak M: Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000;6:2044–2052.
[PubMed]
29.
Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999;5:2223–2229.
[PubMed]
30.
Holstein SA, Hohl RJ: Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001;1:141–149.
[PubMed]
31.
Bogman K, Peyer AK, Torok M, Kusters E, Drewe J: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183–1192.
[PubMed]
32.
Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18:800–806.
[PubMed]
33.
Holmberg M, Sandberg C, Nygren P, Larsson R: Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs 1994;5:598–600.
[PubMed]
34.
Stahlberg D, Rudling M, Angelin B, Björkhem I, Forsell P, Nilsell K, Einarsson K: Hepatic cholesterol metabolism in human obesity. Hepatology 1997;25:1447–1450.
[PubMed]
35.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625–1638.
[PubMed]
36.
Tatsuta M, Iishi H, Baba M, Iseki K, Yano H, Uehara H, Yamamoto R, Nakaizumi A: Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 1998;77:581–587.
[PubMed]
© 2008 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2008
You do not currently have access to this content.
